查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933871

微创肥胖症治疗市场：按类型、技术、最终用户和分销管道分類的全球预测（2026-2032年）

Minimally Invasive Surgery for Obesity Management Market by Type, Technology, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，用于肥胖症管理的微创手术市场价值为 20.8 亿美元，预计到 2026 年将成长至 22.9 亿美元，年复合成长率为 9.45%，到 2032 年将达到 39.2 亿美元。

关键市场统计数据
基准年 2025 20.8亿美元
预计年份：2026年 22.9亿美元
预测年份 2032 39.2亿美元
复合年增长率 (%) 9.45%

针对微创减重手术的策略方法，重点在于临床驱动因素、医疗设备创新以及现代医学中不断发展的照护路径。

微创手术在肥胖症治疗领域已从小众技术发展成为主流临床路径，融合了手术精准性、医疗设备创新和多学科患者照护。在肥胖症盛行率不断上升以及对改善手术全期期预后日益重视的推动下，包括内视镜手术、腹腔镜手术和机器人辅助技术在内的微创方法正在重塑临床医生、医院和门诊手术中心开展可持续减重干预的方式。随着患者越来越寻求治疗方法，临床医生正透过拓展手术选择、引入新的手术平台和完善选择标准来积极应对这一需求。

技术成熟度、分散式护理路径和以价值为导向的支付方趋势如何融合，从而重塑微创减肥手术的采用和提供方式

近年来，一系列变革性变化正在改变肥胖症治疗的模式，并推动微创手术的发展趋势。内视镜和机器人技术的成熟使得手术创伤更小、可重复性更高，从而扩大了适应症范围并降低了手术全期併发症。内视镜技术已从临时性手术发展为更持久的代谢干预，而机器人平台则提高了复杂腹腔镜重组手术的人体工学性能和精准度，迫使外科医生重新评估其手术选择和培训重点。

评估2025年关税变化将如何影响医疗设备贸易，进而改变微创肥胖治疗的供应链、采购惯例和市场进入动态。

将于2025年生效的跨境贸易政策措施可能会对微创肥胖症治疗用外科器械的采购和分销造成重大阻碍。无论关税是选择性地针对特定医疗设备类别，还是整体应用于医疗进口，都将造成成本波动，供应商和医疗机构都必须适应这种波动。对于依赖全球生产网路的製造商而言，关税负担的增加可能会压缩短期利润率，延迟产品上市，并促使其重新评估筹资策略。因此，医院和门诊中心可能面临更高的资本设备和一次性耗材购买成本，这可能会影响采购速度，并使拥有整体拥有成本（TCO）优势的供应商受益。

以细分市场为中心，分析手术类型、平台级技术、临床环境和通路，以识别临床应用和商业性契合度。

深入分析市场细分，可以发现不同手术类型、技术平台、临床环境和通路之间存在不同的临床和商业性动态。在手术类别中，胃束带术、改良胃绕道手术、袖状胃切除术和胃内球囊治疗是主要分类，其重要细分包括：胃束带术包括腹腔镜可调节式和微创式；胃旁路术包括迷你胃旁路术和Roux-en-Y胃旁路术；袖状胃切除术包括内镜下袖状胃成形术和Roux-en-Y胃旁路术；袖状胃内球囊切除术包括内镜下袖状胃成形术和下球囊状置入术和内口服型术。每种手术都有其自身的学习曲线、实证依据和患者选择标准，这些因素都会影响外科医师的选择和医疗机构提供的服务。

区域比较分析突显了美洲、欧洲、中东和非洲以及亚太地区在采用率、报销解读和供应链考量方面的差异。

区域趋势对临床应用、报销架构和供应链韧性有显着影响。在美洲，成熟的医疗保健体系和完善的减重手术计画与日益增长的微创治疗需求并存，这些微创治疗方案旨在缩短住院时间并优化治疗效率。私人保险和混合报销机制促进了以器械为中心的创新和商业性伙伴关係，而州和联邦政策讨论则影响着医疗服务的可及性和合格标准。欧洲、中东和非洲的区域差异则更为明显。西方医疗保健体系强调疗效比较证据和集中式卫生技术评估（HTA）流程，而中东和非洲部分地区则透过公私合营，投资于能力建设和基础设施建设，以扩大外科和内视镜减肥手术的可及性。

竞争格局概述：重点在于产品差异化、实证商业化和策略联盟，以加速临床应用和市场扩张。

微创减重手术领域的竞争格局取决于产品广度、临床证据、培训和服务能力以及策略伙伴关係关係。领先企业透过投资平台互通性、差异化耗材以及整合设备、培训和临床支援的捆绑式服务来实现差异化。监管核准和上市后监测在商业性发展中起着至关重要的作用。积极产生真实世界数据并与支付相关人员合作以证明长期效益的公司通常能够获得更永续的商业性发展轨迹。

製造商、供应商和经销商行动指南：加强证据、降低供应链风险并促进在不同临床环境中的应用

产业领导者应采取一系列切实可行的措施，将洞见转化为快速实施和稳健的商业模式。首先，应优先产生高品质的临床和经济证据，以解答支付方的疑问并帮助优化治疗路径。前瞻性註册研究、可操作的结果研究和成本分析对于确保报销和机构采纳至关重要。其次，应透过区域製造地多元化、关键零件的多通路采购以及策略性库存管理来实现供应链多元化，从而降低关税和物流中断的风险，同时在经济可行的情况下评估近岸外包的可能性。

采用透明且可重复的研究途径，结合一手临床访谈、供应商评估和二手检验，以检验策略性发现及其限制。

这些研究结果背后的调查方法结合了初步的质性检验，以确保其相关性和可靠性。初步数据包括对执业减重外科医生和内视镜外科医生、医院和门诊中心临床计画主任、供应链和采购人员以及支付方和报销专业人员的结构化访谈。与这些相关人员的对话主要围绕着临床偏好、手术流程、培训和资格认证需求、采购决策因素以及他们认为的推广障碍。二次检验则利用监管文件、临床试验註册资讯、同侪审查的临床文献和公共文件，对初步访谈中出现的趋势和主题进行交叉检验和强化。

最终整合临床、商业性和政策驱动因素，以确定微创肥胖治疗的发展方向和相关人员的策略要务。

简而言之，微创肥胖治疗方法正处于一个转折点，技术创新、医疗服务模式的变革以及支付方期望的转变在此交汇融合。从胃束带和胃绕道手术的各种变体到袖状胃切除术和胃内球囊，再到内视镜、腹腔镜和机器人手术平台，多种多样的手术选择为临床医生、製造商和采购商带来了机会和挑战。报销、监管途径和手术能力方面的区域差异凸显了製定本地化策略的必要性，而影响贸易和采购的政策措施则可能对医疗设备的供应和价格趋势产生重大影响。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 微创肥胖症手术市场（按类型划分）

  • 胃束带
    • 腹腔镜可调节
    • 微创
  • 胃绕道手术
    • 迷你胃绕道手术
    • 卢安怀
  • 胃袖切除术
    • 内视镜袖状胃成形术
    • 腹腔镜袖状切除术
  • 胃内球囊
    • 内视镜球囊
    • 可吞嚥气球

9. 按技术分類的微创肥胖症管理手术市场

  • 内视镜
    • 气球
    • 胃镜
  • 腹腔镜手术
    • 能量装置
    • 手持式仪器
    • 订书机
  • 机器人辅助
    • 配件
    • 系统

10. 以最终用户分類的肥胖症微创手术市场

  • 门诊手术中心
  • 医院
  • 专科诊所

11. 微创肥胖症管理手术市场（依通路划分）

  • 直销
    • 场力
    • 机构竞标
  • 线上销售
    • 公司网站
    • 电子商务平台
  • 第三方经销商
    • 国内的
    • 国际的

12. 各地区微创肥胖症手术市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

13. 微创肥胖症手术市场（以群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国微创肥胖症手术市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国微创肥胖症管理手术市场

16. 中国微创肥胖症手术市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Allurion Technologies, Inc.
  • Apollo Endosurgery, Inc.
  • Aspire Bariatrics Ltd.
  • B. Braun Melsungen AG
  • Bariatric Solutions GmbH
  • Boston Scientific Corporation
  • Conmed Corporation
  • Cousin Biotech
  • EndoGastric Solutions, Inc.
  • EndoSphere, Inc.
  • GI Dynamics, Inc.
  • Hologic, Inc.
  • Intuitive Surgical, Inc.
  • Johnson & Johnson Services, Inc.
  • Karl Storz SE & Co. KG
  • Mediflex Surgical Products
  • Medtronic, Inc.
  • Obalon Therapeutics, Inc.
  • Olympus Corporation
  • ReShape Lifesciences, Inc.
  • Smith & Nephew
  • Spatz Medical, Inc.
  • Stryker Corporation
  • TransEnterix
  • USGI Medical, Inc.
  • WL Gore & Associates, Inc.
Product Code: MRR-C36616F69995

The Minimally Invasive Surgery for Obesity Management Market was valued at USD 2.08 billion in 2025 and is projected to grow to USD 2.29 billion in 2026, with a CAGR of 9.45%, reaching USD 3.92 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.08 billion
Estimated Year [2026] USD 2.29 billion
Forecast Year [2032] USD 3.92 billion
CAGR (%) 9.45%

A strategic orientation to minimally invasive obesity surgeries highlighting clinical drivers, device innovation, and care pathway evolution in contemporary practice

Minimally invasive surgery for obesity management has evolved from a niche set of techniques into a mainstream clinical pathway that integrates surgical precision, device innovation, and multidisciplinary patient care. Driven by rising prevalence of obesity and a simultaneous emphasis on improving perioperative outcomes, minimally invasive approaches such as endoscopic procedures, laparoscopic operations, and robotic-assisted techniques are reshaping how clinicians, hospitals, and ambulatory surgical centers approach durable weight-loss interventions. Patients increasingly seek therapies that minimize recovery time and procedural risk while preserving long-term metabolic benefit, and clinicians are responding by expanding procedural portfolios, adopting new platforms, and refining selection criteria.

As a consequence, the ecosystem around obesity surgery is maturing. Medical device manufacturers are investing in procedure-specific instruments, energy devices, stapling systems, endoscopic technologies, and robotics to support reproducible, efficient workflows. Parallel to hardware innovation, payers and health systems are revisiting reimbursement paradigms and pathway optimization to align incentives with value-based outcomes. Training and credentialing programs are adapting to accommodate a broader set of minimally invasive skillsets. Taken together, these dynamics are accelerating clinical adoption while raising the bar for evidence generation, supply-chain reliability, and multidisciplinary care coordination.

How technological maturation, decentralized care pathways, and value-focused payer dynamics are converging to reshape adoption and delivery of minimally invasive bariatric treatments

Recent years have witnessed several transformative shifts that are altering the trajectory of obesity care delivery and the adoption of minimally invasive procedures. Technological maturation in endoscopy and robotics is enabling less invasive, more reproducible interventions that expand candidacy and reduce perioperative morbidity. Endoscopic techniques are moving beyond temporary measures to more durable metabolic interventions, while robotic platforms are enhancing ergonomics and precision for complex laparoscopic reconstructions, prompting surgeons to re-evaluate procedure selection and training priorities.

Concurrently, care pathways are decentralizing as ambulatory surgical centers and specialized clinics take on a larger share of elective bariatric procedures, enabled by standardized protocols and enhanced recovery after surgery frameworks. Payers are increasingly focused on outcomes, prompting bundled-payment pilots and condition-based contracting that reward sustained weight-loss and downstream cost reduction. Patient expectations are shifting toward shorter hospital stays, minimally disruptive approaches, and integrated digital follow-up, which is catalyzing investment in remote monitoring and telehealth-enabled pre- and post-operative care. Supply chain consolidation and partnerships between device makers and providers are emerging as commercially pragmatic responses to pricing pressure, regulatory complexity, and the need for comprehensive training and service models. These shifts collectively favor agile organizations that can align clinical evidence, operational scalability, and patient-centric delivery models.

Assessment of how tariff shifts affecting medical device trade in 2025 could alter supply chains, procurement practices, and access dynamics for minimally invasive obesity therapies

Policy actions affecting cross-border trade in 2025 have the potential to create material friction in the procurement and distribution of surgical equipment used in minimally invasive obesity management. Tariffs, whether applied selectively to device categories or broadly across medical imports, introduce cost volatility that suppliers and providers must manage. For manufacturers that rely on globalized production networks, elevated tariff burdens can prompt near-term margin compression, delayed product launches, and a reassessment of sourcing strategies. In turn, hospitals and ambulatory centers may encounter higher acquisition costs for capital equipment and single-use consumables, which can influence purchasing cadence and favor suppliers that demonstrate total-cost-of-ownership advantages.

Beyond direct cost impacts, tariffs can drive strategic responses that reshape the market. Manufacturers may accelerate localization initiatives, invest in regional manufacturing capacity, or reconfigure bill-of-materials to minimize tariff exposure. Procurement teams may shift toward longer-term contracts, consignment models, or multi-supplier strategies to ensure continuity of supply and predictable budgeting. Equity in access becomes a central concern if increased landed costs are passed on to providers and ultimately to patients through higher procedural fees or constrained program expansion. Finally, regulatory and compliance complexity can increase as importers navigate classification, valuation, and exemption processes, requiring closer collaboration between commercial, legal, and supply-chain functions to mitigate operational risk and preserve patient access to innovative minimally invasive therapies.

Segment-centered insights that dissect procedural subtypes, platform-level technologies, care settings, and distribution pathways to illuminate clinical adoption and commercial fit

A nuanced view of segmentation reveals distinct clinical and commercial dynamics across procedure types, technology platforms, care settings, and distribution pathways. Procedurally, the landscape encompasses gastric band approaches, gastric bypass variants, gastric sleeve techniques, and intragastric balloon therapies, with important sub-distinctions: gastric banding includes laparoscopic adjustable and minimally invasive iterations, gastric bypass options cover mini gastric bypass and Roux-en-Y configurations, gastric sleeve care pathways include endoscopic sleeve gastroplasty as well as laparoscopic sleeve gastrectomy, and intragastric balloon solutions span endoscopic balloon placements and emerging swallowable balloon systems. Each procedural family follows its own learning curve, evidence base, and patient selection criteria, influencing surgeon preference and institutional offering.

From a technology perspective, endoscopic, laparoscopic, and robotic-assisted platforms are central to service delivery. Endoscopic technologies further break down into balloons and gastroscopes that support transoral interventions, laparoscopic approaches rely on energy devices, handheld instruments, and staplers to enable tissue manipulation and resection, and robotic-assisted solutions comprise systems and accessories that augment control and visualization. End users differ in operational emphasis and throughput, with ambulatory surgical centers focusing on efficiency and rapid turnover, hospitals integrating multidisciplinary perioperative care often for complex cases, and specialty clinics offering focused pathways for assessment and longitudinal follow-up. Distribution channels shape commercial access and service models as direct sales operate through field force and institutional tenders, online sales occur through company websites and B2C e-commerce platforms, and third-party distributors manage domestic and international logistics and aftersales support. Understanding the interplay of these segments is essential for aligning product design, training programs, and go-to-market strategies with the clinical workflows and procurement preferences of each stakeholder group.

Regional comparative intelligence highlighting how the Americas, EMEA, and Asia-Pacific diverge in adoption, reimbursement interpretation, and supply chain considerations

Regional dynamics materially influence clinical adoption, reimbursement frameworks, and supply-chain resilience. In the Americas, mature systems and established bariatric programs coexist with rising demand for minimally invasive options that reduce length of stay and optimize throughput; private-pay and mixed reimbursement environments encourage device-focused innovation and commercial partnerships, while state and federal policy debates shape access and eligibility criteria. Across Europe, the Middle East & Africa, heterogeneity is pronounced: Western European health systems emphasize comparative-effectiveness evidence and centralized HTA processes, while parts of the Middle East and Africa are investing in capacity building and infrastructure to expand access to surgical and endoscopic obesity care, often through public-private collaborations.

Asia-Pacific exhibits diverse adoption curves driven by demographic trends, surgical capacity expansion, and localized manufacturing ecosystems. Several markets in the region are rapidly scaling training programs and investing in robotic and endoscopic platforms, driven by both clinical demand and strategic investments in medtech manufacturing. Cross-border supply relationships and regional regulatory harmonization efforts are increasingly important for manufacturers seeking streamlined market entry. Each region requires tailored commercial strategies that accommodate differences in payer architecture, clinician training, regulatory timelines, and procurement behavior, and firms that adapt product configurations, training models, and pricing approaches to local contexts will be better positioned to gain traction.

Competitive landscape overview emphasizing product differentiation, evidence-led commercialization, and strategic partnerships that accelerate clinical adoption and market reach

Competitive dynamics in the minimally invasive obesity surgery ecosystem are shaped by product breadth, clinical evidence, training and service capabilities, and strategic partnerships. Leading participants are differentiating through investments in platform interoperability, differentiated consumables, and bundled service offerings that combine devices, training, and clinical support. Regulatory approvals and post-market surveillance play a decisive role in commercial momentum; companies that proactively generate real-world outcomes and engage with payer stakeholders to demonstrate long-term benefit typically secure a more sustainable commercial trajectory.

Strategic activity also includes alliance formation with hospitals, ambulatory networks, and academic centers to support adoption and credentialing, as well as distribution partnerships that extend geographic reach while managing local regulatory and logistic complexity. Mergers and acquisitions remain a route to rapidly augment portfolio capabilities, particularly in areas such as endoscopic systems, energy devices, and surgical robotics. To remain competitive, companies are prioritizing evidence generation, clinician education programs, and service models that lower the total cost of adoption for hospitals and outpatient facilities, while ensuring that supply continuity and localized support are available in priority markets.

Action-oriented playbook for manufacturers, providers, and distributors to strengthen evidence, de-risk supply chains, and fast-track adoption across diverse care settings

Industry leaders should pursue a set of pragmatic actions to translate insights into accelerated adoption and resilient commercial models. First, prioritize generation of high-quality clinical and economic evidence that addresses payer questions and informs pathway optimization; prospective registries, pragmatic outcome studies, and cost-of-care analyses will be critical to secure reimbursement and institutional adoption. Second, diversify supply chains by combining regional manufacturing, dual-sourcing of critical components, and strategic inventory management to mitigate tariff and logistical disruption risks, while evaluating near-shoring where economically viable.

Third, tailor commercial and training models to the needs of distinct end users: develop fast-track adoption packages for ambulatory surgical centers that emphasize efficiency and disposable kits, while offering comprehensive training and perioperative protocols for hospitals handling complex cases. Fourth, engage early with payers and health-system purchasers to pilot bundled payment models and performance-based contracting that tie reimbursement to patient-centered outcomes. Fifth, invest in digital patient pathways, remote monitoring, and telehealth-enabled follow-up to improve adherence and capture real-world outcomes. Finally, pursue targeted partnerships or licensing arrangements that expand geographic presence or complement core capabilities without incurring prohibitive fixed costs, and maintain an agile pricing strategy that reflects total cost of ownership and value delivered.

Transparent and reproducible research approach combining primary clinical interviews, supplier assessments, and secondary verification to validate strategic insights and limitations

The research methodology underpinning these insights integrates primary qualitative engagement and rigorous secondary verification to ensure relevance and credibility. Primary inputs include structured interviews with practicing bariatric and endoscopic surgeons, clinical program directors in hospitals and ambulatory centers, supply-chain and procurement leaders, and payer and reimbursement specialists. These stakeholder conversations focus on clinical preferences, procedure-level workflows, training and credentialing needs, procurement decision drivers, and perceived barriers to adoption. Secondary validation draws on regulatory filings, clinical trial registries, peer-reviewed clinical literature, and public policy documents to cross-check trends and corroborate themes emerging from primary interviews.

Analytical rigor is achieved through triangulation of data sources and iterative synthesis. Procedural categorizations and technology taxonomies are validated against clinician feedback, while commercial and distribution dynamics are cross-referenced with supplier disclosures and procurement case studies. Limitations are acknowledged: the analysis emphasizes qualitative drivers and strategic implications rather than numerical market sizing, and findings may evolve as new clinical evidence, regulatory decisions, or policy measures emerge. To address this, recommended follow-up includes periodic updates and bespoke deep dives tailored to specific geographies, procedure subtypes, or technology segments.

Final synthesis of clinical, commercial, and policy drivers that converge to determine the trajectory of minimally invasive bariatric care and strategic imperatives for stakeholders

In sum, minimally invasive approaches to obesity management are at an inflection point where technological innovation, shifting care delivery models, and evolving payer expectations converge. The diversity of procedural options-from gastric band and bypass variations to sleeve procedures and intragastric balloons-paired with endoscopic, laparoscopic, and robotic platforms, creates both opportunity and complexity for clinicians, manufacturers, and purchasers. Regional variation in reimbursement, regulatory pathways, and surgical capacity underscores the need for localized strategies, while policy actions affecting trade and procurement can materially influence device availability and pricing dynamics.

Stakeholders who succeed will be those that align robust clinical evidence with pragmatic commercialization and supply strategies, invest in scalable training and service models, and collaborate closely with payers and providers to demonstrate value. By focusing on adaptability, evidence generation, and patient-centric pathways, clinical programs and industry participants can expand access to minimally invasive obesity treatments while maintaining quality and financial sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Minimally Invasive Surgery for Obesity Management Market, by Type

  • 8.1. Gastric Band
    • 8.1.1. Laparoscopic Adjustable
    • 8.1.2. Minimally Invasive
  • 8.2. Gastric Bypass
    • 8.2.1. Mini Gastric Bypass
    • 8.2.2. Roux-En-Y
  • 8.3. Gastric Sleeve
    • 8.3.1. Endoscopic Sleeve Gastroplasty
    • 8.3.2. Laparoscopic Sleeve Gastrectomy
  • 8.4. Intragastric Balloon
    • 8.4.1. Endoscopic Balloon
    • 8.4.2. Swallowable Balloon

9. Minimally Invasive Surgery for Obesity Management Market, by Technology

  • 9.1. Endoscopic
    • 9.1.1. Balloons
    • 9.1.2. Gastroscopes
  • 9.2. Laparoscopic
    • 9.2.1. Energy Devices
    • 9.2.2. Handheld Instruments
    • 9.2.3. Staplers
  • 9.3. Robotic Assisted
    • 9.3.1. Accessories
    • 9.3.2. Systems

10. Minimally Invasive Surgery for Obesity Management Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Minimally Invasive Surgery for Obesity Management Market, by Distribution Channel

  • 11.1. Direct Sales
    • 11.1.1. Field Force
    • 11.1.2. Institutional Tender
  • 11.2. Online Sales
    • 11.2.1. Company Website
    • 11.2.2. E-Commerce Platforms
  • 11.3. Third Party Distributors
    • 11.3.1. Domestic
    • 11.3.2. International

12. Minimally Invasive Surgery for Obesity Management Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Minimally Invasive Surgery for Obesity Management Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Minimally Invasive Surgery for Obesity Management Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Minimally Invasive Surgery for Obesity Management Market

16. China Minimally Invasive Surgery for Obesity Management Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Allurion Technologies, Inc.
  • 17.6. Apollo Endosurgery, Inc.
  • 17.7. Aspire Bariatrics Ltd.
  • 17.8. B. Braun Melsungen AG
  • 17.9. Bariatric Solutions GmbH
  • 17.10. Boston Scientific Corporation
  • 17.11. Conmed Corporation
  • 17.12. Cousin Biotech
  • 17.13. EndoGastric Solutions, Inc.
  • 17.14. EndoSphere, Inc.
  • 17.15. GI Dynamics, Inc.
  • 17.16. Hologic, Inc.
  • 17.17. Intuitive Surgical, Inc.
  • 17.18. Johnson & Johnson Services, Inc.
  • 17.19. Karl Storz SE & Co. KG
  • 17.20. Mediflex Surgical Products
  • 17.21. Medtronic, Inc.
  • 17.22. Obalon Therapeutics, Inc.
  • 17.23. Olympus Corporation
  • 17.24. ReShape Lifesciences, Inc.
  • 17.25. Smith & Nephew
  • 17.26. Spatz Medical, Inc.
  • 17.27. Stryker Corporation
  • 17.28. TransEnterix
  • 17.29. USGI Medical, Inc.
  • 17.30. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC ADJUSTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC ADJUSTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC ADJUSTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY MINI GASTRIC BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY MINI GASTRIC BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY MINI GASTRIC BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROUX-EN-Y, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROUX-EN-Y, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROUX-EN-Y, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC SLEEVE GASTRECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC SLEEVE GASTRECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC SLEEVE GASTRECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC BALLOON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC BALLOON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC BALLOON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SWALLOWABLE BALLOON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SWALLOWABLE BALLOON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SWALLOWABLE BALLOON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTROSCOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTROSCOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTROSCOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENERGY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENERGY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENERGY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY HANDHELD INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY HANDHELD INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY HANDHELD INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY STAPLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY STAPLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY STAPLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY FIELD FORCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY FIELD FORCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY FIELD FORCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INSTITUTIONAL TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INSTITUTIONAL TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INSTITUTIONAL TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COMPANY WEBSITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COMPANY WEBSITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COMPANY WEBSITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DOMESTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DOMESTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DOMESTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTERNATIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTERNATIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTERNATIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN MINIMALLY INVASIVE SURGERY